Illumina, Inc. vs Vipshop Holdings Ltd - ADR — how do they compare? Illumina, Inc. trades at $275.34 (market cap $39.95B), while Vipshop Holdings Ltd - ADR trades at $12.98 (market cap $6.05B). The key difference: Illumina, Inc. is far larger — about 6.6× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.87% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Vipshop Holdings Ltd - ADR for 49 Days on average.
| ILMN | VIPS | |
|---|---|---|
Market Cap | $39.95B | $6.05B |
Volume | 3,169,503 | 3,719,230 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $20.29 |
52-Week Low | $91.00 | $12.09 |
Typical Hold Time | 83 Days | 49 Days |
Enterprise Value | $41.31B | $2.87B |
Dividend Yield | — | 4.87% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Vipshop Holdings (VIPS) trades at $12.98, up 1.61% with mixed technical signals showing neutral overall momentum. The stock trades at attractive valuation multiples including P/E of 4.1x and P/S of 0.4x, supported by strong profitability with 24.4% ROE. Recent earnings showed Q2 2026 miss with $0.12 EPS versus $0.59 expected, reflecting challenging retail conditions as revenue declined to $105.9B in 2025.
The investment case balances deep value metrics against growth headwinds. Analyst consensus targets $16.17 (25% upside) with 54% buy ratings, though recent earnings misses and consumer spending concerns create near-term uncertainty. The company maintains strong cash generation with $9.1B operating cash flow in 2024, supporting shareholder returns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →